How will you mitigate the risk in IPF drug development?
In idiopathic pulmonary fibrosis (IPF), a chronic and progressive restrictive lung disease, a decline in forced vital capacity (FVC) is used as a primary endpoint in clinical trial. As IPF is a restrictive lung disease, lung diffusion measurements like DLCO and TLCO are needed to monitor drug efficacy. The importance of accurate data collection is critical to demonstrating drug effectiveness in clinical trial.
ACHIEVE THE HIGHEST DATA QUALITY AND REDUCE VARIABILITY
ERT has partnered with sponsors in over 1000 drug development studies. Our lung function testing devices, workflow-driven software, and quality services ensure your trial’s spirometry quality and overall site performance and mitigates the risks in IPF drug development. ERT offers an integrated solution to measure lung function endpoints, using integrated devices and software to measure FVC.
Experts in Respiratory Solutions
LEARN MORE ABOUT HOW ERT CAN SUPPORT YOUR CLINICAL TRIAL with an integrated solution
Collects respiratory patient questionnaires for real-time insights into patient safety and study performance.
Captures, reads, and stores ECGs centrally to avoid the risk of false or inaccurate data.
Measures and analyzes imaging endpoints like chest computed tomography (CT) to provide on-demand evidence of drug safety and efficacy.
Talk to a Specialist
Our team of experts is available to address questions you may have about our integrated respiratory solutions. Submit your contact information and we’ll be in touch shortly.